miCure Therapeutics is developing microRNA therapeutics and diagnostics for CNS disorders. Currently miCure Therapeutics is focused Neurodegenerative diseases such as neuropsychiatric diseases (mood disorders).
Mood disorders are a group of high prevalence indications with significant morbidity and potential mortality. The two main subtypes of mood disorder are unipolar (depressive episodes only) and bipolar disorder (mania or hypomania, with depressive episodes). Treatments include medication, psychotherapy, or a combination of the two. With proper treatment, most patients can lead productive lives. However, many patients require second and third line treatments with some presenting severe symptoms even after treatment, being resistant or non-responsive to conventional treatments. miCure Therapeutics develops microRNA-based therapeutics and diagnostics for Major Depression.